Design, Synthesis, and Bioactivity Assessment of Modified Vemurafenib Analog.

Area of Science:

• Oncology
• Medicinal Chemistry

Background:

• Metastatic melanoma is an aggressive cancer with poor outcomes.
• BRAF V600E mutation is present in 40% of melanomas, targeted by vemurafenib.
• Vemurafenib resistance necessitates development of improved therapeutic strategies.

Purpose of the Study:

• To design, synthesize, and characterize novel vemurafenib analogs.
• To enhance anti-proliferative and anti-metastatic effects against human melanoma cells.
• To identify analogs with improved efficacy and selectivity over vemurafenib.

Main Methods:

• Synthesis and characterization of five vemurafenib analogs (RF-86A, RF-87A, RF-94A, RF-94B, RF-96B).
• Evaluation of anti-proliferative activity (IC50) in BRAF V600E-mutated A375 cells.
• Assessment of selectivity using HEK293T cells and inhibition of MMP-2/MMP-9 via migration assays and zymography.

Main Results:

• All analogs induced apoptosis in A375 cells; RF-86A showed the lowest IC50, comparable to vemurafenib.
• RF-86A demonstrated the highest selectivity index among the novel compounds.
• Analogs significantly inhibited matrix metalloproteinases MMP-2 and MMP-9, unlike vemurafenib.

Conclusions:

• Structural modifications of vemurafenib can enhance therapeutic efficacy.
• Novel analogs show potential in overcoming vemurafenib resistance in melanoma.
• These compounds represent a promising strategy for advanced melanoma treatment.